Trial · NCT07888699
WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis
NCT07888699, Phase 2, Not yet recruiting, SPH Sine Pharmaceutical Laboratories Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis. Trials, record NCT07888699. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888699
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis
- NCT number
- NCT07888699
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- SPH Sine Pharmaceutical Laboratories Co., Ltd.
- Conditions
- Bacterial Vaginosis (BV)
- Interventions
- High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole, Placebo Vaginal Capsule Metronidazole
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative recurrence rate of bacterial vaginosis (BV) up to Week-12 visit | From first study drug administration up to Week-12 visit | Percentage of participants with BV recurrence through Week 12 among those who achieve composite cure at or before Week 4. |
| Secondary | BV clinical cure rate at Day-8, Day-15, Week-4 visits | Day8, Day15, Week4 | Percentages of participants achieving protocol-defined clinical cure at each visit. |
| Secondary | BV bacteriological cure rate at Day-8, Day-15, Week-4 visits | Day8, Day15, Week4 | Percentages of participants achieving protocol-defined bacteriological cure at each visit. |
| Secondary | BV composite cure rate at Day-8, Day-15, Week-4 visits | Day8, Day15, Week4 | Percentages of participants achieving protocol-defined composite cure at each visit. |
| Secondary | Cumulative BV recurrence rate up to Week-4 and Week-8 visits | Up to Week-4, Week-8 | Percentage of participants with BV recurrence through Weeks 4 and 8 among those who achieve composite cure at or before Week 4. |
| Secondary | Time to first BV recurrence | From composite cure up to Week-12 | Time from composite cure to first BV recurrence among participants who achieve composite cure at or before Week 4. |
| Secondary | adverse events during treatment and follow-up period | up to 12 weeks | Adverse events summarized by participant counts and severity (mild, moderate, or severe) |
| Secondary | laboratory abnormalities during treatment and follow-up period | up to 12 weeks | abnormal laboratory test results will be listed. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888699
GET https://conductscience.org/api/trials/v1/NCT07888699/registered